For HPLC analysis, a solvent mixture of water and acetonitrile using gradi- ent analysis consisted of 100% water (Solvent A) and 100% acetonitrile (Solvent B). The fl ow rate was 1 mL/min.
Glycation reactions are a possible source of complications in diabetes involving RNA macromolecules.
Mass spectrometry analysis LC/MS and triple quadrupole mass spectrometry (electrospray, MS/ MS multiple reaction monitoring method) were used for detection and identifi cation of the CMAd from synthetic and urine sample specimens.
The Neptune hydrophilic interaction liquid chromatography (HILIC) silica LC column was 2.1 mm × 15 cm and contained 5-μm particles (ES Industries, West Berlin, N.J.). Samples were dissolved in 85% acetonitrile/15% water, and analysis was via LC/MS using HILIC. Separation was done using a binary solvent gradient as Solvent A: HPLC-grade water with 0.1% formic acid, and Solvent B: HPLC-grade acetonitrile with 0.1% formic acid.
The Micromass Q-Tof quadrupole time-of-flight mass spectrometer from Waters (Milford, Mass.) performed full-scan mass spectral analysis. LC/ MS/MS was done on the Waters Quattro Premier XE triple quadrupole mass spectrometer. The ionization method was positive ion electrospray.
DGU-20A5 on-line degasser; SIL-20AC autosampler; Hypercarb 5-μm,
150 × 4.6 mm reversed-phase column; Hypercarb 5-μm, 10 × 4 mm guard column attached to the column head; CTO-20A column oven; and CBM- 20Alite system controller. The SPD-20AV UV/VIS detector operating at a wavelength of 254 nm was used.
Statistical analysis Statistical Analysis System software (SAS, Cary, N.C.) analyzed the clinical parameters data, i.e., BMI, fasting BGL and HbA1c, for the three groups in the study.4
The subjects were divided into three groups—control, obese
AMERICAN LABORATORY • 35 • AUGUST 2015
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52